StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — International sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

Latest, FY2025
49
Period ended Dec 31, 2025
Change on a year earlier
+81.5%
27 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAdempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — International sales ($M) ($M)Year on yearSource
FY2025Dec 31, 202549+81.5%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2024Dec 31, 202427+68.8%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2023Dec 31, 202316+33.3%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2022Dec 31, 202212-60.0%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
FY2021Dec 31, 202130+36.4%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
FY2020Dec 31, 202022+120.0%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
FY2019Dec 31, 201910+100.0%Form 10-K (filed 2022-02-25) ↗
FY2018Dec 31, 20185–Form 10-K (filed 2021-02-25) ↗

Breakdown

What makes up adempas / verquvo (sgc stimulator alliance with bayer — total merck revenue) — international sales ($m)

Cite this data

StockData. (2026). Merck Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — International sales ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_adempas_verquvo_intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.